The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Chernykh I.V.

Ryazan State Medical University, Ryazan, Russia

Shchulkin A.V.

Ryazan State Medical University, Ryazan, Russia

Yakusheva E.N.

Ryazan State Medical University, Ryazan, Russia

Popova N.M.

Ryazan State Medical University, Ruazan, Russia

A role of P-glycoprotein in neurology

Authors:

Chernykh I.V., Shchulkin A.V., Yakusheva E.N., Popova N.M.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(1): 67‑71

DOI: 10.17116/jnevro20171171167-71

Views: 2505

Downloaded: 51

Download PDF (RU)
Contact the author
Table of contents

A ROLE OF P-GLYCOPROTEIN IN NEUROLOGY
A ROLE OF P-GLYCOPROTEIN IN NEUROLOGY

To cite this article:

Chernykh IV, Shchulkin AV, Yakusheva EN, Popova NM. A role of P-glycoprotein in neurology. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(1):67‑71. (In Russ.)
https://doi.org/10.17116/jnevro20171171167-71

 
 
Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Glymphatic dysfunction and sleep diso­rders: indi­rect effe­cts on Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):7-12
Ginkgolide B: mechanisms of neurobiological effe­cts, prospects for use in the therapy of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):22-27
Tremor-dominant form of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):28-35
Nocturia in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):48-54
Long-term follow-up of adult patients with serial and status course of epileptic seizures. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):63-68
Asso­ciations of serum neuromarkers with clinical features of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):145-152
Cognitive impairment in cere­brovascular diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):12-16
Comparative characteristics of neuropsychological and neurometabolic changes in patients with Alzheimer’s disease and vascular cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):17-24
Impairment of atte­ntion and executive functions in chro­nic cere­brovascular disease and Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):25-32
Asse­ssment of the significance of dila­ted peri­vascular spaces and nocture arte­rial hype­rtension in the deve­lopment of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):33-40

On the basis of the analysis of literature data, the authors show a role of P-glycoprotein in the pathogenesis, pharmacotherapy and a prophylaxis of neurologic diseases (Alzheimer’s disease, Parkinson’s disease, epilepsy, stroke).

Keywords:

P-glycoprotein
ABCB1 protein
MDR1
Parkinson’s disease
epilepsy
stroke

Authors:

Chernykh I.V.

Ryazan State Medical University, Ryazan, Russia

Shchulkin A.V.

Ryazan State Medical University, Ryazan, Russia

Yakusheva E.N.

Ryazan State Medical University, Ryazan, Russia

Popova N.M.

Ryazan State Medical University, Ruazan, Russia

List of references:

  1. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell nutans. Biochem Biophis Acta. 1976;455(1):155-162. doi:10.1016/0005-2736(76)90160-7
  2. Sharom FJ. The P-glycoprotein multidrug transporter. Essays Biochem. 2011;50:161-178. doi:10.1042/bse0500161
  3. Lee CY, Lai TY, Wu YM, Hu RH, Lee PH, Hsu LC, Tsai MK. Gene Expression of P-glycoprotein and Cytochrome P450 3A4 in Peripheral Blood Mononuclear Cells and Correlation With Expression in Liver. Transplant Proc. 2010;42(3):834-836. doi:10.1016/j.transproceed.2010.02.048
  4. Choi YH, Yu AM. ABC transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development. Curr Pharm Des. 2014;20:5:793-807.
  5. Callen DF, Baker E, Simmers RN, Seshadri R, Robinson IB. Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum Genet. 1987;77:142-144. doi:10.1007/BF00272381
  6. Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiot. 2008;8:7-8:802-832. doi:10.1080/00498250701867889
  7. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Nat Acad Sci. 2000;97(7):3473-3478. doi:10.1073/pnas.050585397
  8. Yakusheva EN, Shchulkin AV, Chernykh IV, Titov DS. Funkcional'naya aktivnost' glikoproteina-Р pri ehksperimental'nyh manipulyaciyah. Rossiyskiy mediko-biologicheskiy vestnik imeni akademika I.P. Pavlova. 2014;2:76-79.
  9. Abuznait AH, Kaddoumi A. Role of ABC Transporters in the Pathogenesis of Alzheimer’s Disease. ACS chemical neuroscience. 2012;3:11:820-831. doi:10.1021/cn300077c
  10. Kuwahara H, Nishida H, Yokota T. Blood-brain barrier and Alzheimer's disease. Brain Nerve. 2013;65:2:145-151.
  11. Brenn A, Grube M, Jedlitschky G, Fischer A, Strohmeier B, Eiden M, Keller M, Groschup MH, Vogelgesang S. St. John's Wort reduces beta-amyloid accumulation in a double transgenic Alzheimer's disease mouse model-role of P-glycoprotein. Brain Pathol. 2014;24:1:18-24. doi:10.1111/bpa.12069
  12. Deo AK, Borson S, Link JM, Domino K, Eary JF, Ke B, Richards TL, Mankoff DA, Minoshima S, O’Sullivan F, Eyal S, Hsiao P, Miravilla K, Unadkat JD. Activity of P-Glycoprotein, a β-Amyloid Transporter at the Blood-Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease. J Nucl Med. 2014;55:7:1106-1111. doi:10.2967/jnumed.113.130161
  13. Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. The Journal of Clinical Investigation. 2005;115:6:1449-1457. doi:10.1172/JCI24761
  14. Desai BS, Monahan AJ, Carvey PM, Hendey B. Blood—Brain Barrier Pathology in Alzheimer's and Parkinson's Disease: Implications for Drug Therapy. Cell Transplantation. 2007;16:3:285-299. doi:10.3727/000000007783464731
  15. Kiyohara C, Miyake Y, Koyanagi M, Fujimoto T, Shirasawa S, Tanaka K, Fukushima W, Sasaki S, Tsuboi Y, Yamada T, Oeda T, Shimada H, Kawamura N, Sakae N, Fukuyama H, Hirota Y, Nagai M, Kinki F. MDR1 C3435T Polymorphism and Interaction with Environmental Factors in Risk of Parkinson's Disease: A Case-control Study in Japan. Drug Metabolism and Pharmacokinetics. 2013;28:2:138-143. doi:10.2133/dmpk.DMPK-12-RG-075
  16. Braakman HM, Vaessen MJ, Hofman PA, Debeijvan Hall MH, Backes WH, Vles JS, Aldenkamp AP. Cognitive and behavioral complications of frontal lobe epilepsy in children: a review of the literature. Epilepsia. 2011;52:849-856. doi:10.1111/j.1528-1167.2011.03057.x
  17. Bankstahl JP, Hoffmann K, Bethmann K, Löscher W. Glutamate is critically involved in seizure-induced overexpression of P-glycoprotein in the brain. Neuropharmacology. 2008;54:6:1006-1016. doi:10.1016/j.neuropharm.2008.02.008
  18. Gidal BE. P-glycoprotein Expression and Pharmacoresistant Epilepsy: Cause or Consequence? Epilepsy. 2014;14:3:136-138. doi:10.5698/1535-7597-14.3.136
  19. Sun G, Sun X, Guan L. Association of MDR1 gene C3435T polymorphism with childhood intractable epilepsy: a meta-analysis. J Neural Transmis. 2011;121:7:717-724. doi:10.1007/s00702-014-1169-3
  20. Haerian BS, Roslan H, Raymond AA, Tan CT, Lim KS, Zulkifli SZ, Mohamed EHM, Tan HJ, Mohamed Z. ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: A systematic review and meta-analysis. Seizure. 2010;19:6:339-346. doi:10.1016/j.seizure.2010.05.004
  21. Wei-Ping LV, Ren-Feng H, Zhi-Rong S. Associations between the C3435T polymorphism of the ABCB1 gene and drug resistance in epilepsy: a meta-analysis. Int J Clin Exp Med. 2014;7:11:3924-3932.
  22. Li SX, Liu YY, Wang QB. ABCB1 Gene C3435T Polymorphism and Drug Resistance in Epilepsy: Evidence Based on 8604 Subjects. Med Sci Monit. 2015;21:861-868. doi:10.12659/MSM.894023
  23. Cheng JW, Zhang LJ, Hou YQ, Zhao Q, Zhang XJ, Chen XF, Baihttp://www.sciencedirect.com/science/article/pii/S152550501400167X Y. Association between MDR1 C3435T polymorphism and refractory epilepsy in the Chinese population: A systematic review and meta-analysis. Epilepsy Behavior. 2014;36:173-179. doi:10.1016/j.yebeh.2014.05.007
  24. Nicita F, Spalice A, Papetti L, Nikanorova M, Iannetti P, Parisi P. Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy: A pilot study. Seizure. 2014;23:1:36-40. doi:10.1016/j.seizure.2013.09.009
  25. Ji BS, Cen J, He L, Liu M, Liu YQ, Liu L. Modulation of P-glycoprotein in rat brain microvessel endothelial cells under oxygen glucose deprivation. J Pharm Pharmacol. 2013;65:10:1508-1517. doi:10.1111/jphp.12122
  26. Spudich A, Kilic E, Xing H, Kilic U, Rentsch KM, Wunderli-Allenspach H, Bassetti CL, Hermann DM. Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nat Neurosci. 2006;9:4:487-488. doi:10.1038/nn1676
  27. Samoto K, Ikezaki K, Yokoyama N, Fukui M. P-glycoprotein expression in brain capillary endothelial cells after focal ischaemia in the rat. Neurol Res. 1994;16:3:217-223. doi:10.1007/978-3-7091-9334-1_68
  28. Yano K, Takimoto S, Motegi T, Tomono T, Hagiwara M, Idota Y, Morimoto K, Takahara A, Ogihara T. Role of P-glycoprotein in regulating cilnidipine distribution to intact and ischemic brain. Drug Metab Pharmacokinet. 2014;29:3:254-258. doi:10.2133/dmpk.DMPK-13-RG-072
  29. Belayev L, Busto R, Zhao W, Ginsberg MD. Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats. Brain Res. 1996;739:1-2:88-96. doi :10.1016/S0006-8993(96)00815-3
  30. Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, Glahn J, Brandt T, Hacke W, Diener HC. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke. 2001;32:2559-2566. doi:10.1016/S0006-8993(96)00815-3
  31. Stangier J, Clemens A. Pharmacology, pharmacokinetics and pharmacodynamics of dabigatran etexilate an oral direct thrombin inhibitor. Clin Appl Thromb/Hemost. 2009;15:9-16. doi:10.1177/1076029609343004
  32. Pare G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, Axelsson T, Haertter S, Oldgren J, Reilly P, Siegbahn A, Syvänen AC, Wadelius C, Wadelius M, Zimdahl-Gelling H, Yusuf S, Wallentin L. Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding. Circulation. 2013;127:1404-1412. doi:10.1161/CIRCULATIONAHA.112.001233
  33. Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract. 2010;64:956-967. doi:10.1111/j.1742-1241.2009.02286.x
  34. Härtter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol. 2013;75:4:1053-1062. doi:10.1111/j.1365-2125.2012.04453.x
  35. Kubitza D, Becka M, Roth A, Mueck W. Absence of clinically relevant interactions between rivaroxaban — an oral, direct Factor Xa inhibitor--and digoxin or atorvastatin in healthy subjects. J Int Med Res. 2012;40:5:1688-1707. doi:10.1177/030006051204000508
  36. Mendell J, Noveck RJ, Shi M. Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxinadministered alone and in combination. J Cardiovasc Pharmacol. 2012;60:4:335-341. doi:10.1097/FJC.0b013e31826265b6
  37. Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, Zhang G, Shi M. Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor. Am J Cardiovasc Drugs. 2013; http://www.ncbi.nlm.nih.gov/pubmed/23784266. doi:10.1007/s40256-013-0029-0
  38. Shchulkin A.V., Yakusheva E.N., Popova N.M. Rol' glikoproteina-P v racional'noj farmakoterapii v kardiologii. Racional'naya farmakoterapiya v kardiologii. 2013;9:6:687-693.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.